Can a cancer drug stop myeloma before it starts?
NCT ID NCT03236428
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing the drug daratumumab in 42 people with high-risk MGUS or low-risk smoldering multiple myeloma—early, pre-cancerous conditions that can lead to multiple myeloma. The goal is to see if daratumumab can produce a deep response (very good partial response or better) after 20 cycles of treatment. Participants receive the drug intravenously, and the study tracks how well it controls the abnormal plasma cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Daratumumab (Darzalex)
What this could lead to
If successful, this could show that daratumumab can significantly reduce or eliminate abnormal plasma cells, potentially delaying or preventing progression to active multiple myeloma.
What could go wrong
This is a small, early-phase study (42 participants) without a control group, so results may not be definitive. Daratumumab can cause infusion reactions and increase infection risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Karmanos Cancer Insitute
Detroit, Michigan, 48201, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
-
Pacific Cancer Care
Monterey, California, 93940, United States